Aster DM Quality Care Q2 FY27 Revenue Up 19% to ₹2,829 Crore Post-Merger
Aster DM Quality Care reported Q2 FY27 revenue of ₹2,829 crore, up 19% YoY, and operating EBITDA of ₹678 crore, up 25%. The company served 2.2 million patients and realized ₹16.6 crore in synergies. Expansion plans include adding 4,230 beds, targeting over 15,000 total capacity.
The announcement details significant financial growth, strategic expansion plans, and successful integration post-merger, all of which are material factors for investors and stakeholders.
The company reported strong year-on-year growth in revenue and operating EBITDA, alongside successful synergy realization and positive operational highlights. Management expressed confidence in future growth and the integrated platform's performance.
Aster DM Quality Care Limited announced its financial results for the quarter and half-year ended September 30, 2026, marking its first full quarter as a unified entity post-merger. The company reported a significant 19% year-on-year revenue growth to ₹2,829 crore, with operating EBITDA increasing by 25% to ₹678 crore, and operating EBITDA margin expanding to 24%.
Normalised Profit After Tax (PAT) saw a 34% rise to ₹281 crore. The company also achieved ₹16.6 crore in synergies during the quarter, with an annualized run-rate of ₹65 crore, projecting a full potential of approximately ₹200 crore. Management indicated that the synergy benefits are expected to be front-loaded, with the full impact anticipated within the next three to four quarters.
Operational highlights include a 12% increase in patient volume to 2.2 million, and an 8% growth in occupied beds, leading to improved occupancy rates. The company is expanding its capacity with a pipeline of 4,230 additional beds, aiming for a total capacity of over 15,000 beds. Investments in medical technology continue, with over ₹600 crore invested in the last 18 months, including new equipment like LINAC, digital PET-CT, and robots in Q2 FY27.
The company's strategy focuses on strengthening Centres of Excellence and extending clinical expertise across its network. Several hospitals received accreditations, and the company was recognized with awards such as 'Healthcare Brand of the Year' at the ET Healthcare Awards 2026. Management expressed confidence in the integrated platform's ability to drive future growth and deliver better patient outcomes.
What to do with a filing like this
Aster DM Quality Care Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Aster DM Quality Care Limited. Read the original for the full detail.